Trial Outcomes & Findings for A 3 Years Naturalistic Cohort Survey of Altis Single Incision Sling System For Female Stress Urinary Incontinence (NCT NCT04115605)

NCT ID: NCT04115605

Last Updated: 2026-05-26

Results Overview

Treatment success is a composite criterion defined in the protocol as condition improvement by Patient Global Impression of Improvement (PGI-I) reported as "a little better", "much better" or "very much better" and absence of serious or severe related Adverse Events (AEs) one year after implantation. As this definition of success was not restrictive enough, the Scientific Committee proposed a new definition for the treatment success for the statistical analysis, which was defined by PGI-I reported as "very much better" or "much better" and absence of any severe or serious or grade ≥ III of the Clavien-Dindo classification related AEs one year after implantation.

Recruitment status

TERMINATED

Target enrollment

598 participants

Primary outcome timeframe

12 months

Results posted on

2026-05-26

Participant Flow

The first patient was included on 23rd May 2015. The last inclusion occurred on 21st September 2020.

598 subjects were enrolled but 34 subjects were excluded from analysis for the following reasons: 20 GCP compliance deviations, 13 screening failures and 1 implanted patient but whose procedure form was not captured in the eCRF.

Participant milestones

Participant milestones
Measure
Intent-to-treat Population
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but no procedure form completed in eCRF
Overall Study
STARTED
564
Overall Study
2-month postoperative follow-up
545
Overall Study
1-year postoperative follow-up
427
Overall Study
2-year postoperative follow-up
362
Overall Study
3-year postoperative follow-up
307
Overall Study
COMPLETED
307
Overall Study
NOT COMPLETED
257

Reasons for withdrawal

Reasons for withdrawal
Measure
Intent-to-treat Population
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but no procedure form completed in eCRF
Overall Study
Lost to Follow-up
207
Overall Study
Other reason
18
Overall Study
Withdrawal by Subject
16
Overall Study
Treatment failure
7
Overall Study
Adverse Event
4
Overall Study
Death
3
Overall Study
Implantation of another device
2

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but no procedure form completed in eCRF
Age, Continuous
51.5 Years
n=564 Participants
Body Mass Index
25.0 kg/m2
n=564 Participants
Duration since urinary incontinence onset
4.5 Years
n=564 Participants
Pure stress urinary incontinence
399 Participants
n=564 Participants
Sex: Female, Male
Female
564 Participants
n=564 Participants
Sex: Female, Male
Male
0 Participants
n=564 Participants

PRIMARY outcome

Timeframe: 12 months

Population: 400 patients completed the study questionnaires at one year post-implantation but 3 PGI-I data were missing

Treatment success is a composite criterion defined in the protocol as condition improvement by Patient Global Impression of Improvement (PGI-I) reported as "a little better", "much better" or "very much better" and absence of serious or severe related Adverse Events (AEs) one year after implantation. As this definition of success was not restrictive enough, the Scientific Committee proposed a new definition for the treatment success for the statistical analysis, which was defined by PGI-I reported as "very much better" or "much better" and absence of any severe or serious or grade ≥ III of the Clavien-Dindo classification related AEs one year after implantation.

Outcome measures

Outcome measures
Measure
Intent-to-treat Population
n=397 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
Treatment Success
Treatment success as defined in the protocol
375 Participants
Treatment Success
Treatment success as defined by the Scientific Committee
344 Participants

PRIMARY outcome

Timeframe: 12 months

Population: The analyses were performed on the population with available data for PGI-I at 12 months post-implantation.

PGI-I is one of the two outcome measures of the composite primary endpoint. It is a validated question that collects the patients' impression of improvement after the surgery. Among this 7 point-scale ("very much better", "much better", "a little better", "no change", "a little worse", "much worse" and "very much worse"), the patients are asked to check the one number that describes how their urinay tract condition is now, compared with how it's was before the surgery. The percentage of patients who describes "very much better" or "much better" or "little better" and the percentage of patients who describes "very much better" or "much better" were measured.

Outcome measures

Outcome measures
Measure
Intent-to-treat Population
n=397 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
Patient Global Impression of Improvement (PGI-I)
"A little better" or "Much better" or "Very much better"
377 Participants
Patient Global Impression of Improvement (PGI-I)
"Much better" or "Very much better"
349 Participants

PRIMARY outcome

Timeframe: 12 months

Population: The analyses were performed on the population with available data for PGI-I at 12 months post-implantation.

Related Adverse Events (AEs) are one of the two outcome measures of the composite primary endpoint. All AEs related or judged related to the procedure or the device were reported. The percentage of patients without any severe or serious related AEs and the percentage of patients without any severe or serious or grade ≥ III of the Clavien-Dindo classification related AEs were measured.

Outcome measures

Outcome measures
Measure
Intent-to-treat Population
n=397 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
Related Adverse Events
Without any severe or serious related AEs
395 Participants
Related Adverse Events
Without any severe or serious or grade ≥ III of the Clavien-Dindo classification related AEs
389 Participants

SECONDARY outcome

Timeframe: 8 weeks, 24, 36 months

Population: Questionnaires from 522 patients were received and validated (scores and sub-scores were able to be calculated and dates were coherent with a follow-up visit at 8 weeks, 12, 24 or 36 months post-implatantion). The analyses were performed on the population with available data for PGI-I at the different study timepoints.

Treatment success is a composite criterion defined in the protocol as condition improvement by Patient Global Impression of Improvement (PGI-I) reported as "a little better", "much better" or "very much better" and absence of serious or severe related adverse events one year after implantation. As this definition of success was not restrictive enough, the Scientific Committee proposed a new definition for the treatment success for the statistical analysis, which was defined by PGI-I reported as "very much better" or "much better" and absence of any severe or serious or grade ≥ III of the Clavien-Dindo classification related adverse event one year after implantation.

Outcome measures

Outcome measures
Measure
Intent-to-treat Population
n=522 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
Treatment Success
Treatment success as defined in the protocol at 8 weeks post-implantation
365 Participants
Treatment Success
Treatment success as defined by the Scientific Committee at 8 weeks post-implantation
334 Participants
Treatment Success
Treatment success as defined in the protocol at 24 months post-implantation
318 Participants
Treatment Success
Treatment success as defined by the Scientific Committee at 24 months post-implantation
296 Participants
Treatment Success
Treatment success as defined in the protocol at 36 months post-implantation
273 Participants
Treatment Success
Treatment success as defined by the Scientific Committee at 36 months post-implantation
240 Participants

SECONDARY outcome

Timeframe: Baseline, 8 weeks and 12 months

Population: The analyses were performed on the population with available data for CST (negative or postive result) at the different study timepoints.

CST provides the means for documenting stress urinary incontinence. CST is considered "positive" if any leakage is noted with cough or valsava. The percentage of patients with negative test was calculated at baseline, at the post-operative visit and at one year.

Outcome measures

Outcome measures
Measure
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
Cough Stress Test (CST)
Negative CST at baseline
39 Participants
Cough Stress Test (CST)
Negative CST at 8 weeks post-implantation
419 Participants
Cough Stress Test (CST)
Negative CST at 12 months post-implantation
276 Participants

SECONDARY outcome

Timeframe: Baseline, 8 weeks and 12 months

Population: The analyses were performed on the population with available data for PVR at the different study timepoints. PVRs at 8 weeks and 12 months post-implantation were not interpretable because of too many missing data.

Post-void residual (PVR) volume was collected pre- and post implant procedure up to 12 months. If the PVR volume was considered normal by the physician after the procedure, it was not necessary to collect this data at the subsequent follow-up visits.

Outcome measures

Outcome measures
Measure
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
Post-void Residual (PVR) Volume
At baseline
0 mL
Inter-Quartile Range 28.8 • Interval 0.0 to 25.0
Post-void Residual (PVR) Volume
PVR at 8 weeks post-implantation
15 mL
Interval 0.0 to 35.0
Post-void Residual (PVR) Volume
PVR at 12 months post-implantation
15 mL
Interval 0.0 to 33.0

SECONDARY outcome

Timeframe: Baseline, 8 weeks, 12, 24 and 36 months

Population: The analyses were performed on the population with available data for pad use at the different study timepoints. Data obtained either by follow-up or by questionnaires were pooled.

The number of pads used per patient per day was collected. Patients were considered to be pad free if they reported never wearing pads or wear pads just for a sense of security.

Outcome measures

Outcome measures
Measure
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
Pad Use
At baseline
2 number of pads used per patient per day
Inter-Quartile Range 1.9 • Interval 1.0 to 3.0
Pad Use
At 8 weeks post-implantation
0 number of pads used per patient per day
Inter-Quartile Range 1.1 • Interval 0.0 to 1.0
Pad Use
At 12 months post-implantation
0 number of pads used per patient per day
Inter-Quartile Range 1.1 • Interval 0.0 to 1.0
Pad Use
At 24 months post-implantation
0 number of pads used per patient per day
Inter-Quartile Range 1.3 • Interval 0.0 to 1.0
Pad Use
At 36 months post-implantation
0 number of pads used per patient per day
Inter-Quartile Range 1.0 • Interval 0.0 to 1.0

SECONDARY outcome

Timeframe: Baseline, 8 weeks, 12, 24 and 36 months

Population: The analyses were performed on the population with available data for ICIQ-UI at the different study timepoints.

The ICIQ-UI Short Form is a seft-administred questionnaire to evaluate the frequency, severity and impact on quality of life of urinary incontinence. Question 1 asked, "How often do you leak urine?" Subjects were instructed to select among "none" (0), "about once a week or less often" (1), "2 or 3 times a week" (2), "about once a day" (3), "several times a day" (4), and "all the time" (5). Question 2 asked, "How much urine do you usually leak (whether you wear protection or not)?" Patients responded with "none" (0), "a small amount" (2), "a moderate amount" (4) or "a large amount (6). Question 3 asked, "Overall, how much does leaking urine interfere with your everyday life?" Participants chose a number from 0 (not at all) to 10 (a great deal). Question 1, 2 and 3 are summed to compute the total ICIQ score.The total score range is then a minimum of 0 to a maximum of 21.

Outcome measures

Outcome measures
Measure
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
International Consultation on Incontinence Questionnaire (ICIQ-UI)
At baseline
14 Score from 0 to 21
Interval 12.0 to 16.0
International Consultation on Incontinence Questionnaire (ICIQ-UI)
At 8 weeks post-implantation
0 Score from 0 to 21
Interval 0.0 to 5.0
International Consultation on Incontinence Questionnaire (ICIQ-UI)
At 12 months post-implantation
0 Score from 0 to 21
Interval 0.0 to 5.0
International Consultation on Incontinence Questionnaire (ICIQ-UI)
At 24 months post-implantation
1 Score from 0 to 21
Interval 0.0 to 6.0
International Consultation on Incontinence Questionnaire (ICIQ-UI)
At 36 months post-implantation
1 Score from 0 to 21
Interval 0.0 to 6.0

SECONDARY outcome

Timeframe: 8 weeks, 12, 24, 36 months

Population: Questionnaires from 522 patients were received and validated (scores and sub-scores were able to be calculated and dates were coherent with a follow-up visit at 8 weeks, 12, 24 or 36 months post-implatantion). The analyses were performed on the population with available data for the Subject global statisfaction questionnaire at the different study timepoints.

This non-validated questionnaire provides additional information concerning patient satisfaction. This survey consists of two questions: Question 1 "how satisfied are you with your surgery?". Among 5 point-scale (very satisfied, satisfied, not satisfied-not dissatisfied, dissatisfied and very dissatified), patient check the one items that best describes the subject satisfaction. We measured the percentage of patients who were very satisfied and satisfied. The patients answer the question "Do you recommend this operation to a friend?" by "yes" or "no". We measured the percentage of patients who answered "yes".

Outcome measures

Outcome measures
Measure
Intent-to-treat Population
n=522 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
Subject Global Satisfaction Questionnaire
Are very satisfied or satisfied with this operation at 8 weeks
93.1 Percentage of patients
Interval 91.8 to 94.4
Subject Global Satisfaction Questionnaire
Would recommand this operation to a friend at 8 weeks
97.1 Percentage of patients
Interval 95.4 to 98.8
Subject Global Satisfaction Questionnaire
Are very satisfied or satisfied with this operation at 12 months
90.4 Percentage of patients
Interval 87.5 to 93.3
Subject Global Satisfaction Questionnaire
Would recommand this operation to a friend at 12 months
97.2 Percentage of patients
Interval 95.6 to 98.8
Subject Global Satisfaction Questionnaire
Are very satisfied or satisfied with this operation at 24 months
91.4 Percentage of patients
Interval 88.3 to 94.5
Subject Global Satisfaction Questionnaire
Would recommand this operation to a friend at 24 months
95.8 Percentage of patients
Interval 93.6 to 98.0
Subject Global Satisfaction Questionnaire
Are very satisfied or satisfied with this operation at 36 months
89.9 Percentage of patients
Interval 86.6 to 93.5
Subject Global Satisfaction Questionnaire
Would recommand this operation to a friend at 36 months
94.5 Percentage of patients
Interval 91.9 to 97.1

SECONDARY outcome

Timeframe: Baseline, 8 weeks, 12, 24, 36 months

Population: The analyses were performed on the population with available data for I-QoL at the different study timepoints.

The Incontinence quality of life questionnaire (I-QoL) is a validated survey questionnaire with 22 items that are scored on a 5-point Likert scale. The I-QOL and its subcale scores are computed by adding each item response, subtracting the lowest possible score and diving that sum by the possible raw score range. The scores are then transformed to have a range from 0 (maximum problem) to 100 (no problem at all).

Outcome measures

Outcome measures
Measure
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
Incontinence Quality of Life Questionnaire (I-QoL)
At 36 months post-implantation
94.8 Score from 0 to 100
Interval 87.5 to 100.0
Incontinence Quality of Life Questionnaire (I-QoL)
At baseline
53.4 Score from 0 to 100
Interval 37.8 to 71.6
Incontinence Quality of Life Questionnaire (I-QoL)
At 8 weeks post-implantation
93.2 Score from 0 to 100
Interval 83.0 to 98.8
Incontinence Quality of Life Questionnaire (I-QoL)
At 12 months post-implantation
95.5 Score from 0 to 100
Interval 88.6 to 98.9
Incontinence Quality of Life Questionnaire (I-QoL)
At 24 months post-implantation
95.5 Score from 0 to 100
Interval 88.6 to 98.9

SECONDARY outcome

Timeframe: Baseline, 8 weeks, 12, 24, 36 months

Population: The analyses were performed on the population with available data for PISQ-12 at the different study timepoints.

The Pelvic organ/urinary incontinence sexual questionnaire (PISQ-12) is a validated and reliable short form questionnaire including 12 questions that evaluates sexual function in heterosexual women with urinary incontinence and/or pelvic organ prolapse. Reponses are graded on a 5-point Likert scale from "never" to "always". The scores were calculated at each assessment visit.

Outcome measures

Outcome measures
Measure
Intent-to-treat Population
n=564 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
Impact on Sexual Function Assessed by the Pelvic Organ/Urinary Incontinence Sexual Questionnaire (PISQ 12)
At baseline
35 Score from 5 to 60
Interval 30.0 to 40.0
Impact on Sexual Function Assessed by the Pelvic Organ/Urinary Incontinence Sexual Questionnaire (PISQ 12)
At 8 weeks post-implantation
37 Score from 5 to 60
Interval 33.0 to 41.0
Impact on Sexual Function Assessed by the Pelvic Organ/Urinary Incontinence Sexual Questionnaire (PISQ 12)
At 12 months post-implantation
38 Score from 5 to 60
Interval 33.0 to 41.0
Impact on Sexual Function Assessed by the Pelvic Organ/Urinary Incontinence Sexual Questionnaire (PISQ 12)
At 24 months post-implantation
38.0 Score from 5 to 60
Interval 33.8 to 42.0
Impact on Sexual Function Assessed by the Pelvic Organ/Urinary Incontinence Sexual Questionnaire (PISQ 12)
At 36 months post-implantation
38.0 Score from 5 to 60
Interval 31.6 to 42.0

SECONDARY outcome

Timeframe: 8 weeks, 24, 36 months

Population: Questionnaires from 522 patients were received and validated (scores and sub-scores were able to be calculated and dates were coherent with a follow-up visit at 8 weeks, 12, 24 or 36 months post-implatantion). The analyses were performed on the population with available data for PGI-I at the different study timepoints.

PGI-I is a validated question that collects the patients' impression of improvement after the surgery. Among this 7 point-scale ("very much better", "much better", "a little better", "no change", "a little worse", "much worse" and "very much worse"), the patients are asked to check the one number that describes how their urinay tract condition is now, compared with how it's was before the surgery. The percentage of patients who describes "very much better" or "much better" or "little better" was measured.

Outcome measures

Outcome measures
Measure
Intent-to-treat Population
n=522 Participants
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
Patient Global Impression of Improvement (PGI-I)
At 8 weeks post-implantation
371 Participants
Patient Global Impression of Improvement (PGI-I)
At 24 months post-implantation
321 Participants
Patient Global Impression of Improvement (PGI-I)
At 36 months post-implantation
277 Participants

Adverse Events

Intent-to-treat Population

Serious events: 3 serious events
Other events: 145 other events
Deaths: 3 deaths

Serious adverse events

Serious adverse events
Measure
Intent-to-treat Population
n=564 participants at risk
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
General disorders
Vaginal mesh exposure
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Product Issues
Urethral mesh extrusion
0.35%
2/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed

Other adverse events

Other adverse events
Measure
Intent-to-treat Population
n=564 participants at risk
All patients for whom a procedure was performed even if the Altis® Single Incision Sling was not implanted among the eligible population excluding major deviation, patient with no information at baseline, or patients implanted but not procedure form completed in eCRF
Injury, poisoning and procedural complications
Bladder Perforation
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Reproductive system and breast disorders
Dyspareunia
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Renal and urinary disorders
Dysuria
2.0%
11/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Musculoskeletal and connective tissue disorders
Non-Urogenital Pain
10.6%
60/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Injury, poisoning and procedural complications
Paresthesia
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Renal and urinary disorders
Pollakiuria
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Injury, poisoning and procedural complications
Post-procedural Haematoma
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Renal and urinary disorders
Slow Stream
0.35%
2/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Reproductive system and breast disorders
Synechiae
0.18%
1/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Renal and urinary disorders
Urgency
1.4%
8/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Renal and urinary disorders
Urgency Urinary Incontinence
1.2%
7/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Renal and urinary disorders
Urinary Retention
5.0%
28/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Renal and urinary disorders
Urinary Tract Infection
2.0%
11/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Reproductive system and breast disorders
Urogenital Pain
0.71%
4/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
General disorders
Vaginal Mesh Exposure
1.1%
6/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
Injury, poisoning and procedural complications
Vaginal Perforation
0.35%
2/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed
General disorders
Vaginal Thread Exposure
0.53%
3/564 • 3 years
Only Adverse Events related or judged related to the procedure or the device were collected, monitored and assessed

Additional Information

Mrs Martine Dehez, Manager, Clinical Quality & EU Clinical Research

Coloplast Manufacturing France

Phone: +33634408340

Results disclosure agreements

  • Principal investigator is a sponsor employee By signing the study agreement, the investigators have undertaken to keep confidential and not to disclose to any third party without the prior formal written consent of the sponsor any data relating to the study, its results, and its follow-up that is not in the public domain.
  • Publication restrictions are in place

Restriction type: OTHER